Revolution Medicines officer granted options and shares

Revolution Medicines, Inc. officer Stephen Michael Kelsey reported equity awards that increased his direct holdings.

Rhea-AI Filing Summary

Revolution Medicines, Inc. officer Stephen Michael Kelsey reported equity awards that increased his direct holdings. He received a stock option covering 47,600 shares of common stock at an exercise price of $0.00 per share, characterized as a grant or award acquisition. He also acquired 21,100 shares of common stock as a separate grant, bringing his directly held common shares to 299,700, which includes 94,676 restricted stock units. The option vests in equal monthly installments over four years starting March 1, 2026, with one forty-eighth of the shares vesting each month so that all option shares are fully vested on the fourth anniversary, contingent on his continued service.

Insider Trade Summary

Grant/Award: 68,700 shares

Grant/Award 2 txns

Insider Kelsey Stephen Michael

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	47,600	$0.00	$0.00
Grant/Award	Common Stock	21,100	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 47,600 contracts (Direct); Common Stock — 299,700 shares (Direct)

Footnotes (2)

1. F1. Includes 94,676 restricted stock units.
2. F2. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

FAQ

What equity awards did Stephen Michael Kelsey report for Revolution Medicines (RVMD)?

Stephen Michael Kelsey reported receiving a stock option for 47,600 shares and a grant of 21,100 shares of Revolution Medicines common stock. These awards were characterized as grant or award acquisitions and increased his directly held equity position in the company.

How many Revolution Medicines (RVMD) shares does Kelsey hold after this Form 4?

After these transactions, Stephen Michael Kelsey directly holds 299,700 shares of Revolution Medicines common stock. This figure includes 94,676 restricted stock units, reflecting both previously held and newly granted equity reported in this Form 4 filing.

What are the vesting terms of Kelsey’s new stock option at Revolution Medicines (RVMD)?

The stock option for 47,600 shares vests monthly over four years starting March 1, 2026. One forty-eighth of the initially subject shares vests each month, with full vesting on the fourth anniversary, conditioned on his continued service through each vesting date.

Was there a purchase price for the Revolution Medicines (RVMD) stock option grant?

The reported stock option grant to Stephen Michael Kelsey shows a per-share transaction price of $0.00. This indicates it was granted as compensation rather than bought in an open-market purchase, consistent with a typical equity award structure for company officers.

How is the 94,676 figure related to Kelsey’s Revolution Medicines (RVMD) holdings?

The 94,676 figure represents restricted stock units included in Stephen Michael Kelsey’s total of 299,700 common shares. These RSUs are part of his overall reported beneficial ownership, alongside directly held common stock and newly reported equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 09:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelsey Stephen Michael

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		21,100	A	$0	299,700(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$102.02	03/01/2026		A		47,600		(2)	02/28/2036	Common Stock	47,600	$0	47,600	D

Explanation of Responses:

1. Includes 94,676 restricted stock units.

2. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

President, Research and Development

	/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.